{"analyses":[{"ciLowerLimit":"2.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"78.42","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.002","paramType":"Odds Ratio (OR)","paramValue":"14.63","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"5.93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"99.99","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"30.37","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"6.1","value":"1.1"},{"groupId":"OG001","lowerLimit":"12.1","upperLimit":"28.2","value":"18.9"},{"groupId":"OG002","lowerLimit":"27.0","upperLimit":"43.0","value":"34.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"133"}],"units":"Participants"}],"description":"PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants with baseline PRO Measure EL hair loss ≥2 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}